Compare Inovio Pharmaceuticals Inc (INO) vs Zoom Video Communications, Inc. (ZM) Price & Performance

INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.

The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.

Zoom Communications (ZM) trades at $89.77, down 1.49% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 77.4% gross margins and 42% net income margins, while recent AI-focused acquisitions and APAC leadership appointments signal growth initiatives. Q1 2026 earnings beat expectations with $1.55 EPS versus $1.42 expected.

Investment outlook remains positive with a $118.79 consensus price target offering 32% upside potential, though risks include competitive pressure from Microsoft and Google, insider selling activity, and fluctuating cash flow trends. Wall Street sentiment is mixed with 39% buy ratings versus 55% hold recommendations.